🔗 Visit the ClinicalTrials.gov page for NCT02061761
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. | BMC Med | 2016 | 0.83 |
| 2 | Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. | Immunotherapy | 2015 | 0.81 |
| 3 | Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. | Oncoimmunology | 2014 | 0.81 |
| 4 | Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. | Gynecol Oncol | 2016 | 0.79 |
| 5 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. | Pharmaceuticals (Basel) | 2015 | 0.78 |
| 6 | Lymphocyte-activation gene-3, an important immune checkpoint in cancer. | Cancer Sci | 2016 | 0.76 |
| 7 | The controversial role of TNF in melanoma. | Oncoimmunology | 2015 | 0.75 |